EU to review GSK womb cancer treatment
British pharmaceutical giant, GlaxoSmithKline PLC, said on Tuesday that the European Union’s drug watchdog will study a new treatment for a common type of womb cancer for potential approval in the European market. The European Medicines Agency agreed to review the drug, dostarlimab, which has the brand name Jemperli, the company said in a statement.